On May 21, 2021, Novavax announced that the full results from the Phase 3, randomized, observer-blinded, placebo-controlled trial conducted in more than 15,000 adults in the United Kingdom had been published in a manuscript posted to the preprint server medRxiv.

Conclusions stated that a two-dose regimen of Novavax COVID-19 vaccine candidate, NVX-CoV2373, conferred nearly 90% protection against a blend of prototype and variant COVID-19, demonstrated high efficacy against the B.1.1.7 variant, and demonstrated a reassuring safety profile.

The study assessed efficacy during a period when the B.1.1.7 variant strain of the virus was emerging and circulating widely in the United Kingdom. It is now the most widely circulating variant strain of the virus in the United States.